Overview

Vascular Inflammation and Cholesterol Lowering Therapy

Status:
Withdrawn
Trial end date:
2020-10-01
Target enrollment:
0
Participant gender:
All
Summary
This study aim to detect change in vascular inflammation following intense lipid lowering therapy
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rigshospitalet, Denmark
Treatments:
Evolocumab
Criteria
Inclusion Criteria:

- treatment with PCSK-9 inhibitors

Exclusion Criteria:

- Infection Pregnancy Severe claustrophobia Weight >140 kg